PULSE ALERT: Bragar Eagel & Squire, P.C. is Investigating Pulse Biosciences, Inc. on Behalf of Pulse Stockholders and Encourages Investors to Contact the Firm

Reading Time:
2
 minutes
Posted: February 12, 2022
A J
Share this article
In this Article

NEW YORK--(BUSINESS WIRE)--#Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) on behalf of Pulse stockholders. Our investigation concerns whether Pulse has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On February 8, 2022, Pulse issued a press release “announc[ing] an update to its recent U.S. Food and Drug Administration (FDA) 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System’s current labeling.” Specifically, Pulse advised that following its submission of “ a 510(k) in December 2021 to add the treatment of sebaceous hyperplasia to the CellFX System’s indications for use in the United States”, “ [o]n February 5, 2022, the Company received an Additional Information (“AI”) letter from the FDA”, in which “the FDA stated it did not believe the Company provided sufficient clinical evidence at this time to support the expanded indication for use, and that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study.”

On this news, Pulse’s stock price fell $3.74 per share, or 34.44%, to close at $7.12 per share on February 8, 2022.

If you purchased or otherwise acquired Pulse shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Contacts

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Alexandra B. Raymond, Esq.

(212) 355-4648

investigations@bespc.com
www.bespc.com

Follow CEO Today

Just for you
enus $1x3monthspromo static banner 728x90 c1 v1 (1)
Partner Banner
Free CEO Today Newsletter
Subscribe to CEO Today for the latest news every week.

About CEO Today

CEO Today Online and CEO Today magazine are dedicated to providing CEOs and C-level executives with the latest corporate developments, business news and technological innovations.

Follow CEO Today